Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Adv Ther (Weinh). 2021 Mar 18;4(8):2100034. doi: 10.1002/adtp.202100034

Figure 1.

Figure 1.

The surface density of pMHC on synthetic APCs impacts T cell binding. (A) SynAPCs are formulated with DSPC, cholesterol, and DSPE-PEG-maleimide. pMHC engineered with a C-terminal cysteine residue reacts with free maleimide on the liposome surface. (B) Table summarizing liposome characteristics for various DSPE-PEG-maleimide ratios. (C) DLS of synAPCs showing a monodisperse peak after pMHC conjugation. (D) Binding curve of pMHC targeted synAPCs staining target T cells as quantified as MFI by flow cytometry. A 0.5% DSPE-PEG-maleimide ratio was chosen for subsequent experiments. Data fit to a one-site model of receptor-ligand binding.